1460879695-fbf2f138-27e3-4faf-9af6-9aecce51016c

1. A compound having the formula:
wherein Z is selected from the group consisting of O, NR4, S(O)n, NR4CO, CONR4, or NR4CONR4,
wherein -G-H-J, alternatively, is selected from
wherein each H and J are independently selected,
C\u2014B-A-, -D-E-F, and -G-H-J are chemical moieties, wherein
A, D and G are independently selected from the group consisting of:
(a) a single bond, (b) \u2014(C1-8 alkyl)-, (c) \u2014(C2-8 alkenyl)-, (d) \u2014(C2-8 alkynyl)-, wherein
i) 0-4 carbon atoms in any of (b)-(d) immediately above optionally is replaced by a moiety selected from the group consisting of \u2014O\u2014, \u2014S(O)p\u2014, \u2014NR6\u2014, \u2014(C\u2550O)\u2014, \u2014S(O)pNR6\u2014, \u2014NR6S(O)p\u2014, and \u2014NR6S(O)pNR6\u2014,
ii) any of (b)-(d) immediately above optionally is substituted with one or more R5 groups, and
iii) any of (b)-(d) immediately above optionally is substituted with \u2014(C1-8 alkyl)-R5 groups;

(e) \u2014O\u2014, (f) \u2014NR6\u2014, (g) \u2014S(O)p\u2014, (h) \u2014C(O)\u2014, (i) \u2014C(O)O\u2014, (j) \u2014OC(O)\u2014, k) \u2014OC(O)O\u2014, (l) \u2014C(O)NR6\u2014, (m) \u2014NR6CO\u2014, (n) \u2014NR6C(O)NR6\u2014, (o) \u2014C(\u2550NR6)\u2014, (p) \u2014C(\u2550NR6)O\u2014, (q) \u2014OC(\u2550NR6)\u2014, (r) \u2014C(\u2550NR6)NR6\u2014, (s) \u2014NR6C(\u2550NR6)\u2014, (t) \u2014C(\u2550S)\u2014, (u) \u2014C(\u2550S)NR6\u2014, (v) \u2014NR6C(\u2550S)\u2014, (w) \u2014C(O)S\u2014, (x) \u2014SC(O)\u2014, (y) \u2014OC(\u2550S)\u2014, (z) \u2014C(\u2550S)O\u2014, (aa) \u2014NR6(CNR6)NR6\u2014, (bb) \u2014CR6R6C(O)\u2014, (cc) \u2014C(O)NR6(CR6R6)t\u2014, (dd) a 3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
(ee) a 3-14 member saturated, unsaturated, or aromatic carbocycle, and
(ff) \u2014(CR6R6)t\u2014,

wherein (dd) or (ee) is optionally substituted with one or more R5 groups;
B, E, and H are independently selected from the group consisting of:
(a) a single bond,
(b) a 3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
(c) a 3-14 member saturated, unsaturated, or aromatic carbocycle,

wherein (b) or (c) is optionally substituted with one or more R5 groups;
(d) \u2014(C1-8 alkyl)-, (e) \u2014(C2-8 alkenyl)-, (f) \u2014(C2-8 alkynyl)-, wherein
i) 0-4 carbon atoms in any of (d)-(f) immediately above optionally is replaced by a moiety selected from the group consisting of \u2014O\u2014, \u2014S(O)p\u2014, \u2014NR6\u2014, \u2014(C\u2550O)\u2014, \u2014C(\u2550NR6)\u2014, \u2014S(O)pNR6\u2014, \u2014NR6S(O)p\u2014, and \u2014NR6S(O)pNR6\u2014,
ii) any of (d)-(f) immediately above optionally is substituted with one or more R5 groups, and
iii) any of (d)-(f) immediately above optionally is substituted with \u2014(C1-8 alkyl)-R5 groups;

and (g) \u2014(CR6R6)t\u2014,

C, F, and J are independently selected from the group consisting of:
(a) hydrogen, (c) F, (d) Cl, (e) Br, (f) I, (g) \u2014CF3, (h) \u2014CN, (i) \u2014N3 (j) \u2014NO2, (k) \u2014NR6(CR6R6)tR8, (l) \u2014OR8, (m) \u2014S(O)p(CR6R6)tR8, (n) \u2014C(O)(CR6R6)tR8, (o) \u2014OC(O)(CR6R6)tR8, (p) \u2014SC(O)(CR6R6)tR8, (q) \u2014C(O)O(CR6R6)tR8, (r) \u2014NR6C(O)(CR6R6)tR8, (s) \u2014C(O)NR6(CR6R6)tR8, (t) \u2014C(\u2550NR6)(CR6R6)tR8, (u) \u2014C(\u2550NNR6R6)(CR6R6)tR8, (v) \u2014C(\u2550NNR6C(O)R6)(CR6R6)tR8, (w) \u2014C(\u2550NOR8)(CR6R6)tR8, (x) \u2014NR6C(O)O(CR6R6)tR8, (y) \u2014OC(O)NR6(CR6R6)tR8, (z) \u2014NR6C(O)NR6(CR6R6)tR8, (aa) \u2014NR6S(O)p(CR6R6)tR8, (bb) \u2014S(O)pNR6(CR6R6)tR8, (cc) \u2014NR6S(O)pNR6(CR6R6)tR8, (dd) \u2014NR6R8, (ee) \u2014NR6(CR6R6)R8, (ff) \u2014OH, (gg) \u2014NR8R8, (hh) \u2014OCH3, (ii) \u2014S(O)pR8, (jj) \u2014NC(O)R8, (kk) \u2014NR6C(NR6)NR6R8, (ll) a C1-8 alkyl group, (mm) a C2-8 alkenyl group, (nn) a C2-8 alkynyl group, (oo) a 3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (pp) a 3-14 member saturated, unsaturated, or aromatic carbocycle, (qq) \u2014(CR6R6)tNR6(CR6R6)tR8, (rr) \u2014N(CR6R6)tR8C\u2550O(CR6R6)tR8, (ss) \u2014(CR6R6)tN(CR6R6)tR8(CR6R6)tR8, (tt) \u2014(CR6R6)tNR6(C\u2550O)(CR6R6)tR8, (uu)- haloalkyl, (vv) \u2014C(O)(CR6)(CR6R6)tR8R8, (ww) \u2014(CR6R6)tC(O)NR8R8, (xx) \u2014(CR6R6)tC(O)O(CR6R6)tR8, (yy) \u2014NR6C(O)CR8R8R8, (zz) \u2014N(CR6R6)tR8C(O)R8, and (aaa) \u2014S(O)pNR8R8;

wherein (ll) through (pp) is optionally substituted with one or more R7 groups;
R5 is selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) \u2014CF3, (g) \u2014CN, (h) \u2014N3 (i) \u2014NO2, (j) \u2014NR6R6, (k) \u2014OR8, (l) \u2014NR6(CNR6)NR6R6, (m) \u2014C1-8 alkyl, (n) \u2014C1-8 alkenyl, (o) \u2014C1-8 alkynyl, (p) \u2014(C1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (q) \u2014(C1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic carbocycle), (r)-haloalkyl, (s) \u2014SR6, (t)-3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (u)-3-14 member saturated, unsaturated, or aromatic carbocycle; alternatively, two R5 groups are taken together to form a carbocycle,
wherein (m) through (r) and (t) through (u) is optionally substituted with one or more R8;

R6 is selected from (a) hydrogen, (b) \u2014C1-8 alkyl or alternatively two R6 groups are taken together to form a carbocycle, (c)-haloalkyl, (d)-3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (e)-3-14 member saturated, unsaturated, or aromatic carbocycle;
wherein (b) through (e) is optionally substituted with one or more R8;
R7 is selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) \u2014CF3, (g) \u2014CN, (h) \u2014N3 (i) \u2014NO2, (j) \u2014NR6R6, (k) \u2014OR6, (l) \u2014NR6(CNR6)NR6R6, (m) \u2014C1-8 alkyl, (n) \u2014C1-8 alkenyl, (o) \u2014C1-8 alkynyl, (p) \u2014(C1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (q) \u2014(C1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic carbocycle), (r)-haloalkyl, (s) \u2014NR6R8, (t) \u2014OR8, (u) \u2014(CR6R6)tNR6R8, (v) \u2014CR6R8R8, (w) \u2014SR6, (x)-3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (y)-3-14 member saturated, unsaturated, or aromatic carbocycle, (z) \u2014(CR6R6)tC(O)NR8R8, (aa) \u2014S(O)pR8, (bb) \u2014NR6C(O)NR6R6, (cc) \u2014NR6C(O)R6, and (dd) \u2014C(\u2550NR6)NR6R6;
wherein (m) through (q) and (x) through (y) are optionally substituted with one or more R9;

R8 is selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) \u2014CF3, (g) \u2014CN, (h) \u2014N3 (i) \u2014NO2, (j) \u2014NR6R9, (k) \u2014OR9, (l) \u2014NR6(CNR6)NR6R6, (m) \u2014C1-8 alkyl, (n) \u2014C1-8 alkenyl, (o) \u2014C1-8 alkynyl, (p) \u2014(C1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (q) \u2014(C1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic carbocycle), (r)-3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (s)-3-14 member saturated, unsaturated, or aromatic carbocycle, (t)-haloalkyl, (u) \u2014C(O)(CR6R6)tR9, (v) \u2014SR6, (w) \u2014OC(O)(CR6R6)tR9, (x) \u2014NR6C(O)NR6R9, (y) \u2014NR6C(O)R9, (z) \u2014NR6(CNR9)(NR6R6), (aa) \u2014ONR6(CNR6)NR6R6, (bb) \u2014C(\u2550NR9)NR6R6, (cc) \u2014S(O)pR9, (dd) \u2014(CR6R6)tC(O)NR6R9, (ee) \u2014(CR6R6)tOR9, and (ff) \u2014(CR6R6)tNR6R9;
wherein (m) through (s) is optionally substituted with one or more R9;

R9 is selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) \u2014CF3, (g) \u2014CN, (h) \u2014N3 (i) \u2014NO2, (j) \u2014NR6R10, (k) \u2014OR6, (l) \u2014NR6(CNR6)NR6R6, (m) \u2014C(O)(CR6R6)tNR6R6, (n) \u2014C1-8 alkyl, (o) \u2014C1-8 alkenyl, (p) \u2014C1-8 alkynyl, (q)-3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (r)-3-14 member saturated, unsaturated, or aromatic carbocycle, (s)-haloalkyl, (t) \u2014(CR6R6)tOR6, (u) \u2014O(CR6R6)tNR6R10, (v) \u2014C(O)R6, (w) \u2014SR6, (x) \u2014C(O)OR10, (y) \u2014S(O)pR6, (z) \u2014(C1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (aa) \u2014(C1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic carbocycle), (bb) \u2014O(CR6R6)tOR6, (cc) \u2014C(\u2550NR6)NR6R6, (dd) \u2014ONR6R6, (ee) \u2014NR6C(O)NR6R6, (ff) \u2014O(CR6R6)tOR6, (gg) \u2014NR6C(O)R6, and (hh) \u2014(CR6R6)tNR6R10;
wherein (n) through (r) and (z) through (aa) is optionally substituted with one or more R10;

R10 is selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) \u2014CF3, (g) \u2014CN, (h) \u2014N3 (i) \u2014NO2, (j) \u2014NR6R6, (k) \u2014OR6, (l) \u2014NR6(CNR6)NR6R6, (m) \u2014C(O)(CR6R6)tNR6R6, (n) \u2014C1-8 alkyl, (o) \u2014C1-8 alkenyl, (p) \u2014C1-8 alkynyl, (q)-3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (r)-3-14 member saturated, unsaturated, or aromatic carbocycle, (s)-haloalkyl, (t) \u2014(CR6R6)tOR6, (u) \u2014O(CR6R6)tNR6R6, (v) \u2014C(O)R6, (w) \u2014SR6, (x) \u2014C(O)OR6, (y) \u2014S(O)pR6, (z) \u2014(C1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (aa) \u2014(C1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic carbocycle), (bb) \u2014O(CR6R6)tOR6, (cc) \u2014C(\u2550NR6)NR6R6, (dd) \u2014ONR6R6, (ee) \u2014NR6C(O)NR6R6, (ff) \u2014O(CR6R6)tOR6, (gg) \u2014NR6C(O)R6, and (hh) \u2014(CR6R6)tNR6R6;
optionally, wherein either -D-E-F or -G-H-J is hydrogen;

p is 0, 1, or 2, and
t is 0, 1, 2, or 3,
or a pharmaceutically acceptable salt, ester, tautomer, or prodrug thereof.
2. The compound according to claim 1 having the formula:
wherein Z is selected from the group \u2014NR4, \u2014NR4CO\u2014, \u2014CONR4\u2014, and \u2014NR4CONR4\u2014; or a pharmaceutically acceptable salt, ester, tautomer, or prodrug thereof.
3. The compound according to claim 2, wherein Z is \u2014NR4CONR4\u2014; or a pharmaceutically acceptable salt, ester, tautomer, or prodrug thereof.
4. The compound according to claim 3 having the formula:
wherein Z is \u2014NHCONH\u2014; or a pharmaceutically acceptable salt, ester, tautomer, or prodrug thereof.
5. The compound according claim 4, wherein
A is selected from
(a) a 3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
(b) a 3-14 member saturated, unsaturated, or aromatic carbocycle, and
(c) a single bond,

wherein (a) or (b) is optionally substituted with one or more R5 groups;
B is selected from (a) \u2014(C1-8 alkyl)-, (b) \u2014(C2-8 alkenyl)-, (c) \u2014(C2-8 alkynyl)-, (d) a single bond, wherein
i) 0-4 carbon atoms in any of (a)-(c) immediately above optionally is replaced by a moiety selected from the group consisting of \u2014O\u2014, \u2014S(O)p\u2014, \u2014NR6\u2014, \u2014(C\u2550O)\u2014, \u2014C(\u2550NR6)\u2014, \u2014S(O)pNR6\u2014, and \u2014NR6S(O)pNR6\u2014,
ii) any of (a)-(c) immediately above optionally is substituted with one or more R5 groups, and
iii) any of (a)-(c) immediately above optionally is substituted with \u2014(C1-C8 alkyl)-R5 groups, and

C is selected from (a) NH2, (b) \u2014NHC(\u2550NH)NH2 and (c) hydrogen;
or a pharmaceutically acceptable salt, ester, tautomer, or prodrug thereof.
6. The compound according to claim 5, wherein
A is selected from azepanyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, pyridinyl, cyclohexenyl, cyclohexadienyl, dihydropyridyl, furanyl, tetrahydrofuranyl, tetrahydropyridyl, azetidinyl, pyrrolidinyl, piperidinyl, and piperidenyl;
wherein any of A immediately above optionally is substituted with one or more R5 groups;
alternatively, A is a single bond;
B is selected from (a) \u2014(C1-8 alkyl)-, wherein
i) 0-4 carbon atoms in (a) immediately above optionally is replaced by a moiety selected from the group consisting of \u2014O\u2014, \u2014S(O)p\u2014, \u2014NR6\u2014, \u2014(C\u2550O)\u2014, \u2014S(O)pNR6\u2014, and \u2014NR6S(O)pNR6\u2014,
ii) (a) immediately above optionally is substituted with one or more R5 groups, and
iii) (a) immediately above optionally is substituted with \u2014(C1-8 alkyl)-R5 groups; and

alternatively, B is a single bond;
C is selected from (a) NH2, (b) \u2014NHC(\u2550NH)NH2 and (c) hydrogen;
or a pharmaceutically acceptable salt, ester, tautomer, or prodrug thereof.
7. The compound according to claim 6, wherein C\u2014B-A- is selected from the group consisting of:
hydrogen,
or a pharmaceutically acceptable salt, ester, tautomer, or prodrug thereof.
8. The compound according to claim 4, wherein G is selected from
(a) a 3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
(b) a 3-14 member saturated, unsaturated, or aromatic carbocycle, and
(c) a single bond;

wherein (a) or (b) is optionally substituted with one or more R5 groups,
or a pharmaceutically acceptable salt, ester, tautomer, or prodrug thereof.
9. The compound according to claim 5, wherein R5 is selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) \u2014CF3, (g) \u2014CN, (h) \u2014N3 (i) \u2014NO2, (j) \u2014NH2, (k) \u2014OR6, (l) \u2014NHC(\u2550NH)NH2, (m) \u2014C1-8 alkyl, (n) \u2014C1-8 alkenyl, (o) \u2014C1-8 alkynyl, (p) \u2014(C1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (q) \u2014(C1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic carbocycle), (r)-haloalkyl, (s) \u2014SR6, (t)-3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (u)-3-14 member saturated, unsaturated, or aromatic carbocycle; alternatively, two R5 groups are taken together to form a carbocycle, or a pharmaceutically acceptable salt, ester, tautomer, or prodrug thereof.
10. The compound according to claim 5, wherein R6 is selected from (a) hydrogen, (b) \u2014C1-8 alkyl or alternatively two R6 groups are taken together to form a carbocycle, (c)-haloalkyl, (d)-3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (e)-3-14 member saturated, unsaturated, or aromatic carbocycle, or a pharmaceutically acceptable salt, ester, tautomer, or prodrug thereof.
11. The compound according to claim 8, wherein G is selected from azepanyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, pyridinyl, cyclohexenyl, cyclohexadienyl, dihydropyridyl, furanyl, tetrahydrofuranyl, tetrahydropyridyl, azetidinyl, pyrrolidinyl, piperidinyl, piperidenyl, and a single bond; or a pharmaceutically acceptable salt, ester, tautomer, or prodrug thereof.
12. The compound according to claim 11, wherein -G-H-J is selected from: hydrogen,
or a pharmaceutically acceptable salt, ester, tautomer, or prodrug thereof.
13. The compound according to claim 12 wherein each -G-H-J is selected from:
hydrogen,
wherein R5 is as defined in claim 10,
or a pharmaceutically acceptable salt, ester, tautomer, or prodrug thereof.
14. The compound according to any of claims 1 to 13 that binds to a ribosome.
15. The compound according to claim 14, wherein the ribosome is a bacterial ribosome.
16. The compound according to any of the compounds in Table 1 or a pharmaceutically acceptable salt, ester, tautomer, or prodrug thereof.
17. The pharmaceutical composition comprising a compound according to any one of claims 1-16, or a pharmaceutically acceptable salt, ester, tautomer, or prodrug thereof, and a pharmaceutically acceptable carrier.
18. A method for treating, preventing or reducing the risk of a disease state in a human or animal comprising administering to a human or animal in need thereof an effective amount of a compound according to any one of claims 1-16, or a pharmaceutically acceptable salt, ester, tautomer, or prodrug thereof.
19. A method of treating a microbial infection in a human or animal comprising administering to the human or animal an effective amount of a compound according to any one of claims 1-16, or a pharmaceutically acceptable salt, ester, tautomer, or prodrug thereof.
20. The use of a compound according to any one of claims 1-16, or a pharmaceutically acceptable salt, ester, tautomer, or prodrug thereof, in the manufacture of a medicament for treating a microbial infection in a human or animal.
21. A method of treating or reducing the risk of a microbial infection in a human or animal comprising administering to the human or animal an effective amount of a compound according to any one of claims 1-16, or a pharmaceutically acceptable salt, ester, tautomer, or prodrug thereof, wherein the microbial infection is selected from the group consisting of:
a skin infection, a Gram positive infection, a Gram negative infection, nosocomial a skin infection, a Gram positive infection, a Gram negative infection, nosocomial pneumonia, community acquired pneumonia, post-viral pneumonia, hospital acquired pneumoniaventilator associated pneumonia, a respiratory tract infection such as chronic respiratory tract infection (CRTI), acute pelvic infection, a complicated skin and skin structure infection, a skin and soft tissue infection (SSTI) including uncomplicated skin and soft tissue infections (uSSTI)s and complicated skin and soft tissue infections, an abdominal infection, a complicated intra-abdominal infection, a urinary tract infection, bacteremia, septicemia, endocarditis, an atrio-ventricular shunt infection, a vascular access infection, meningitis, surgical prophylaxis, a peritoneal infection, a bone infection, a joint infection, a methicillin-resistant Staphylococcus aureus infection, a vancomycin-resistant Enterococci infection, a linezolid-resistant organism infection, a Bacillus anthracis infection, a Francisella tularensis infection, a Yersinia pestis infection, and tuberculosis.
22. The method or use according to any one of claims 18-21 wherein the compound, or a pharmaceutically acceptable salt, ester, tautomer, or prodrug thereof, is administered otically, ophthalmically, nasally, orally, parenterally, topically, or intravenously.
23. A method of synthesizing a compound according to any of claims 1-16, or a pharmaceutically acceptable salt, ester, tautomer, or prodrug thereof.
24. A medical device containing a compound according to any one of claims 1-16, or a pharmaceutically acceptable salt, ester, tautomer, or prodrug thereof.
25. The medical device according to claim 24, wherein the device is a stent.
26. A compound having the formula:
wherein V is independently selected from \u2014CR4a\u2014 or \u2014N\u2014,
W is O, NR1, NOR1, or S, alternatively W\u2550 is selected from the combination of HO\u2014 and H\u2014 both attached to the same carbon atom or the combination of (C1-8 alkyl)O\u2014 and H\u2014 both attached to the same carbon atom;
XY represents a single bond or a double bond such that when XY is a single bond, X is selected from O, NR2, and S(O)n and Y is C\u2014R3, and when XY is a double bond, X is N and Y is a carbon atom,
Z is selected from the group consisting of O, NR4, S(O)n, NR4CO, CONR4, or NR4CONR4,
R1 is selected from H and C1-8 alkyl,
R2 is selected from H and C1-8 alkyl,
R3 is selected from H and C1-8 alkyl,
R4 is selected from H and C1-8 alkyl,
R4a is selected from H and C1-8 alkyl,
n is 0, 1, or 2,
alternatively, -G-H-J is selected from
wherein each H and J are independently selected,
C\u2014B-A-, -D-E-F, and -G-H-J are chemical moieties, wherein
A, D and G are independently selected from the group consisting of:
(a) a single bond, (b) \u2014(C1-8 alkyl)-, (c) \u2014(C2-8 alkenyl)-, (d) \u2014(C2-8 alkynyl)-, wherein
i) 0-4 carbon atoms in any of (b)-(d) immediately above optionally is replaced by a moiety selected from the group consisting of \u2014O\u2014, \u2014S(O)p\u2014, \u2014NR6\u2014, \u2014(C\u2550O)\u2014, \u2014S(O)pNR6\u2014, \u2014NR6S(O)p\u2014, and \u2014NR6S(O)pNR6\u2014,
ii) any of (b)-(d) immediately above optionally is substituted with one or more R5 groups, and
iii) any of (b)-(d) immediately above optionally is substituted with \u2014(C1-8 alkyl)-R5 groups;

(e) \u2014O\u2014, (f) \u2014NR6\u2014, (g) \u2014S(O)p\u2014, (h) \u2014C(O)\u2014, (i) \u2014C(O)O\u2014, (j) \u2014OC(O)\u2014, k) \u2014OC(O)O\u2014, (l) \u2014C(O)NR6\u2014, (m) \u2014NR6CO\u2014, (n) \u2014NR6C(O)NR6\u2014, (o) \u2014C(\u2550NR6)\u2014, (p) \u2014C(\u2550NR6)O\u2014, (q) \u2014OC(\u2550NR6)\u2014, (r) \u2014C(\u2550NR6)NR6\u2014, (s) \u2014NR6C(\u2550NR6)\u2014, (t) \u2014C(\u2550S)\u2014, (u) \u2014C(\u2550S)NR6\u2014, (v) \u2014NR6C(\u2550S)\u2014, (w) \u2014C(O)S\u2014, (x) \u2014SC(O)\u2014, (y) \u2014OC(\u2550S)\u2014, (z) \u2014C(\u2550S)O\u2014, (aa) \u2014NR6(CNR6)NR6\u2014, (bb) \u2014CR6R6C(O)\u2014, (cc) \u2014C(O)NR6(CR6R6)t\u2014, (dd) a 3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
(ee) a 3-14 member saturated, unsaturated, or aromatic carbocycle, and
(ff) \u2014(CR6R6)t\u2014,

wherein (dd) or (ee) is optionally substituted with one or more R5 groups;
B, E, and H are independently selected from the group consisting of:
(a) a single bond,
(b) a 3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
(c) a 3-14 member saturated, unsaturated, or aromatic carbocycle,

wherein (b) or (c) is optionally substituted with one or more R5 groups;
(d) \u2014(C1-8 alkyl)-, (e) \u2014(C2-8 alkenyl)-, (f) \u2014(C2-8 alkynyl)-, wherein
i) 0-4 carbon atoms in any of (d)-(f) immediately above optionally is replaced by a moiety selected from the group consisting of \u2014O\u2014, \u2014S(O)p\u2014, \u2014NR6\u2014, \u2014(C\u2550O)\u2014, \u2014C(\u2550NR6)\u2014, \u2014S(O)pNR6\u2014, \u2014NR6S(O)p\u2014, and \u2014NR6S(O)pNR6\u2014,
ii) any of (d)-(f) immediately above optionally is substituted with one or more R5 groups, and
iii) any of (d)-(f) immediately above optionally is substituted with \u2014(C1-8 alkyl)-R5 groups;

and (g) \u2014(CR6R6)t\u2014,

C, F, and J are independently selected from the group consisting of:
(a) hydrogen, (c) F, (d) Cl, (e) Br, (f) I, (g) \u2014CF3, (h) \u2014CN, (i) \u2014N3 (j) \u2014NO2, (k) \u2014NR6(CR6R6)tR8, (l) \u2014OR8, (m) \u2014S(O)p(CR6R6)tR8, (n) \u2014C(O)(CR6R6)tR8, (o) \u2014OC(O)(CR6R6)tR8, (p) \u2014SC(O)(CR6R6)tR8, (q) \u2014C(O)O(CR6R6)tR8, (r) \u2014NR6C(O)(CR6R6)tR8, (s) \u2014C(O)NR6(CR6R6)tR8, (t) \u2014C(\u2550NR6)(CR6R6)tR8, (u) \u2014C(\u2550NNR6R6)(CR6R6)tR8, (v) \u2014C(\u2550NNR6C(O)R6)(CR6R6)tR8, (w) \u2014C(\u2550NOR8)(CR6R6)tR8, (x) \u2014NR6C(O)O(CR6R6)tR8, (y) \u2014OC(O)NR6(CR6R6)tR8, (z) \u2014NR6C(O)NR6(CR6R6)tR8, (aa) \u2014NR6S(O)p(CR6R6)tR8, (bb) \u2014S(O)pNR6(CR6R6)tR8, (cc) \u2014NR6S(O)pNR6(CR6R6)tR8, (dd) \u2014NR6R8, (ee) \u2014NR6(CR6R6)R8, (ff) \u2014OH, (gg) \u2014NR8R8, (hh) \u2014OCH3, (ii) \u2014S(O)pR8, (jj) \u2014NC(O)R8, (kk) \u2014NR6C(NR6)NR6R8, (ll) a C1-8 alkyl group, (mm) a C2-8 alkenyl group, (nn) a C2-8 alkynyl group, (oo) a 3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (pp) a 3-14 member saturated, unsaturated, or aromatic carbocycle, (qq) \u2014(CR6R6)tNR6(CR6R6)tR8, (rr) \u2014N(CR6R6)tR8C\u2550O(CR6R6)tR8, (ss) \u2014(CR6R6)tN(CR6R6)tR8(CR6R6)tR8, (tt) \u2014(CR6R6)tNR6(C\u2550O)(CR6R6)tR8, (uu)- haloalkyl, (vv) \u2014C(O)(CR6)(CR6R6)tR8R8, (ww) \u2014(CR6R6)tC(O)NR8R8, (xx) \u2014(CR6R6)tC(O)O(CR6R6)tR8, (yy) \u2014NR6C(O)CR8R8R8, (zz) \u2014N(CR6R6)tR8C(O)R8, and (aaa) \u2014S(O)pNR8R8;

wherein (ll) through (pp) is optionally substituted with one or more R7 groups;
R5 is selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) \u2014CF3, (g) \u2014CN, (h) \u2014N3 (i) \u2014NO2, (j) \u2014NR6R6, (k) \u2014OR8, (l) \u2014NR6(CNR6)NR6R6, (m) \u2014C1-8 alkyl, (n) \u2014C1-8 alkenyl, (o) \u2014C1-8 alkynyl, (p) \u2014(C1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (q) \u2014(C1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic carbocycle), (r)-haloalkyl, (s) \u2014SR6, (t)-3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (u)-3-14 member saturated, unsaturated, or aromatic carbocycle; alternatively, two R5 groups are taken together to form a carbocycle,
wherein (m) through (r) and (t) through (u) is optionally substituted with one or more R8;

R6 is selected from (a) hydrogen, (b) \u2014C1-8 alkyl or alternatively two R6 groups are taken together to form a carbocycle, (c)-haloalkyl, (d)-3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (e)-3-14 member saturated, unsaturated, or aromatic carbocycle;
wherein (b) through (e) is optionally substituted with one or more R8;
R7 is selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) \u2014CF3, (g) \u2014CN, (h) \u2014N3 (i) \u2014NO2, (j) \u2014NR6R6, (k) \u2014OR6, (l) \u2014NR6(CNR6)NR6R6, (m) \u2014C1-8 alkyl, (n) \u2014C1-8 alkenyl, (o) \u2014C1-8 alkynyl, (p) \u2014(C1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (q) \u2014(C1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic carbocycle), (r)-haloalkyl, (s) \u2014NR6R8, (t) \u2014OR8, (u) \u2014(CR6R6)tNR6R8, (v) \u2014CR6R8R8, (w) \u2014SR6, (x)-3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (y)-3-14 member saturated, unsaturated, or aromatic carbocycle, (z) \u2014(CR6R6)tC(O)NR8R8, (aa) \u2014S(O)pR8, (bb) \u2014NR6C(O)NR6R6, (cc) \u2014NR6C(O)R6, and (dd) \u2014C(\u2550NR6)NR6R6;
wherein (m) through (q) and (x) through (y) are optionally substituted with one or more R9;

R8 is selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) \u2014CF3, (g) \u2014CN, (h) \u2014N3 (i) \u2014NO2, (j) \u2014NR6R9, (k) \u2014OR9, (l) \u2014NR6(CNR6)NR6R6, (m) \u2014C1-8 alkyl, (n) \u2014C1-8 alkenyl, (o) \u2014C1-8 alkynyl, (p) \u2014(C1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (q) \u2014(C1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic carbocycle), (r)-3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (s)-3-14 member saturated, unsaturated, or aromatic carbocycle, (t)-haloalkyl, (u) \u2014C(O)(CR6R6)tR9, (v) \u2014SR6, (w) \u2014OC(O)(CR6R6)tR9, (x) \u2014NR6C(O)NR6R9, (y) \u2014NR6C(O)R9, (z) \u2014NR6(CNR9)(NR6R6), (aa) \u2014ONR6(CNR6)NR6R6, (bb) \u2014C(\u2550NR9)NR6R6, (cc) \u2014S(O)pR9, (dd) \u2014(CR6R6)tC(O)NR6R9, (ee) \u2014(CR6R6)tOR9, and (ff) \u2014(CR6R6)tNR6R9;
wherein (m) through (s) is optionally substituted with one or more R9;

R9 is selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) \u2014CF3, (g) \u2014CN, (h) \u2014N3 (i) \u2014NO2, (j) \u2014NR6R10, (k) \u2014OR6, (l) \u2014NR6(CNR6)NR6R6, (m) \u2014C(O)(CR6R6)tNR6R6, (n) \u2014C1-8 alkyl, (o) \u2014C1-8 alkenyl, (p) \u2014C1-8 alkynyl, (q)-3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (r)-3-14 member saturated, unsaturated, or aromatic carbocycle, (s)-haloalkyl, (t) \u2014(CR6R6)tOR6, (u) \u2014O(CR6R6)tNR6R10, (v) \u2014C(O)R6, (w) \u2014SR6, (x) \u2014C(O)OR10, (y) \u2014S(O)pR6, (z) \u2014(C1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (aa) \u2014(C1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic carbocycle), (bb) \u2014O(CR6R6)tOR6, (cc) \u2014C(\u2550NR6)NR6R6, (dd) \u2014ONR6R6, (ee) \u2014NR6C(O)NR6R6, (ff) \u2014O(CR6R6)tOR6, (gg) \u2014NR6C(O)R6, and (hh) \u2014(CR6R6)tNR6R10;
wherein (n) through (r) and (z) through (aa) is optionally substituted with one or more R10;

R10 is selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) \u2014CF3, (g) \u2014CN, (h) \u2014N3 (i) \u2014NO2, (j) \u2014NR6R6, (k) \u2014OR6, (l) \u2014NR6(CNR6)NR6R6, (m) \u2014C(O)(CR6R6)tNR6R6, (n) \u2014C1-8 alkyl, (o) \u2014C1-8 alkenyl, (p) \u2014C1-8 alkynyl, (q)-3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (r)-3-14 member saturated, unsaturated, or aromatic carbocycle, (s)-haloalkyl, (t) \u2014(CR6R6)tOR6, (u) \u2014O(CR6R6)tNR6R6, (v) \u2014C(O)R6, (w) \u2014SR6, (x) \u2014C(O)OR6, (y) \u2014S(O)pR6, (z) \u2014(C1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (aa) \u2014(C1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic carbocycle), (bb) \u2014O(CR6R6)tOR6, (cc) \u2014C(\u2550NR6)NR6R6, (dd) \u2014ONR6R6, (ee) \u2014NR6C(O)NR6R6, (ff) \u2014O(CR6R6)tOR6; (gg) \u2014NR6C(O)R6, and (hh) \u2014(CR6R6)tNR6R6;
optionally, wherein either the group -D-E-F or the group -G-H-J is absent, but both -D-E-F and -G-H-J are not simultaneously absent;

p is 0, 1, or 2, and
t is 0, 1, 2, or 3,
or a pharmaceutically acceptable salt, ester, tautomer, or prodrug thereof.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method of wireless communication, comprising:
receiving an indication of time and frequency resources of future activity of a mobile wireless service (MWS) radio access technology (RAT); and
scheduling communications of a wireless connectivity network (WCN) radio access technology (RAT) based at least in part on the indication of the time and frequency resources of the future activity.
2. The method of claim 1, in which the scheduling communications of the WCN RAT is further based at least in part on a scheduled transmission power for a transmission of the MWS RAT or the WCN RAT.
3. The method of claim 2, in which the scheduling communications of the WCN RAT is further based at least in part on a frequency separation between resources to be used by the MWS RAT and resources to be used by the WCN RAT.
4. The method of claim 3, in which the scheduling communications of the WCN RAT comprises changing a planned WCN communication mode.
5. The method of claim 3, further comprising cancelling a planned downlink reception of the WCN RAT during a scheduled time for uplink communication of the MWS RAT.
6. An apparatus for wireless communication, comprising:
means for receiving an indication of time and frequency resources of future activity of a mobile wireless service (MWS) radio access technology (RAT); and
means for scheduling communications of a wireless connectivity network (WCN) radio access technology (RAT) based at least in part on the indication of the time and frequency resources of the future activity.
7. The apparatus of claim 6, in which the means for scheduling communications of the WCN RAT is further based at least in part on a scheduled transmission power for a transmission of the MWS RAT or the WCN RAT.
8. The apparatus of claim 7, in which the means for scheduling communications of the WCN RAT is further based at least in part on a frequency separation between resources to be used by the MWS RAT and resources to be used by the WCN RAT.
9. The apparatus of claim 8, in which the means for scheduling communications of the WCN RAT comprises means for changing a planned WCN communication mode.
10. The apparatus of claim 8, further comprising means for cancelling a planned downlink reception of the WCN RAT during a scheduled time for uplink communication of the MWS RAT.
11. A computer program product, comprising:
a computer-readable medium having program code recorded thereon, the program code comprising:
program code to receive an indication of time and frequency resources of future activity of a mobile wireless service (MWS) radio access technology (RAT); and
program code to schedule communications of a wireless connectivity network (WCN) radio access technology (RAT) based at least in part on the indication of the time and frequency resources of the future activity.
12. The computer program product of claim 11, in which the program code to schedule communications of the WCN RAT is further based at least in part on a scheduled transmission power for a transmission of the MWS RAT or the WCN RAT.
13. The computer program product of claim 12, in which the program code to schedule communications of the WCN RAT is further based at least in part on a frequency separation between resources to be used by the MWS RAT and resources to be used by the WCN RAT.
14. The computer program product of claim 13, in which the program code to schedule communications of the WCN RAT comprises program code to change a planned WCN communication mode.
15. The computer program product of claim 13, in which the program code further comprises program code to cancel a planned downlink reception of the WCN RAT during a scheduled time for uplink communication of the MWS RAT.
16. An apparatus configured for wireless communication, the apparatus comprising:
at least one processor; and
a memory coupled to the at least one processor, wherein the at least one processor is configured:
to receive an indication of time and frequency resources of future activity of a mobile wireless service (MWS) radio access technology (RAT); and
to schedule communications of a wireless connectivity network (WCN) radio access technology (RAT) based at least in part on the indication of the time and frequency resources of the future activity.
17. The apparatus of claim 16, in which the at least one processor configured to schedule communications of the WCN RAT is further based at least in part on a scheduled transmission power for a transmission of the MWS RAT or the WCN RAT.
18. The apparatus of claim 17, in which the at least one processor configured to schedule communications of the WCN RAT is further based at least in part on a frequency separation between resources to be used by the MWS RAT and resources to be used by the WCN RAT.
19. The apparatus of claim 18, in which the at least one processor configured to schedule communications of the WCN RAT comprises program code to change a planned WCN communication mode.
20. The apparatus of claim 18, in which the at least one processor is further configured to cancel a planned downlink reception of the WCN RAT during a scheduled time for uplink communication of the MWS RAT.